Patients and treatment characteristics
| Parameter . | CB recipient . | BM recipient . |
|---|---|---|
| No. of patients (M/F) | 10 (8/2) | 19 (11/8) |
| Mean age (range) | ||
| Patients | 12.6 y (3.0-34.6) | 15.0 y (3.3-36.4) |
| Donors | 0 | 20.0 y (9.0-48.4) |
| Diagnosis, (%) | ||
| Acute lymphoblastic leukemia | 4 (40) | 4 (21) |
| Acute myeloid leukemia | 2 (20) | 5 (26) |
| Chronic myeloid leukemia | 2 (20) | 3 (16) |
| Myelodysplastic syndrome | 1 (10) | 1 (5) |
| Severe aplastic anemia | 1 (10) | 6 (32) |
| Leukemia stage at transplantation, no. (%) | ||
| First complete remission | 1 (13) | 7 (58) |
| Second complete remission | 5 (62) | 2 (17) |
| First chronic phase | 0 (0) | 3 (25) |
| First acute phase | 2 (25) | 0 (0) |
| Median (range) nucleated cell no. infused (× 108/kg) | 0.29 (0.11-0.70) | 2.93 (0.91-5.74) |
| Median (range) CD34+ cell no. infused (× 105/kg) | 0.14 (0.05-0.38) | 6.08 (2.05-17.86) |
| Conditioning, no. (%) | ||
| Cyclophosphamide based | 8 (80) | 15 (79) |
| Melphalan based | 2 (20) | 4 (21) |
| Total body irradiation | 6 (60) | 6 (32) |
| Antithymocyte globulin | 6 (60) | 5 (26) |
| GVHD prophylaxis, no. (%) | ||
| Cyclosporine | 6 (60) | 0 (0) |
| Cyclosporine + methotrexate | 0 (0) | 19 (100) |
| Cyclosporine + prednisolone | 4 (40) | 0 (0) |
| Posttransplantation G-CSF, no. (%) | 9 (90) | 9 (47) |
| Parameter . | CB recipient . | BM recipient . |
|---|---|---|
| No. of patients (M/F) | 10 (8/2) | 19 (11/8) |
| Mean age (range) | ||
| Patients | 12.6 y (3.0-34.6) | 15.0 y (3.3-36.4) |
| Donors | 0 | 20.0 y (9.0-48.4) |
| Diagnosis, (%) | ||
| Acute lymphoblastic leukemia | 4 (40) | 4 (21) |
| Acute myeloid leukemia | 2 (20) | 5 (26) |
| Chronic myeloid leukemia | 2 (20) | 3 (16) |
| Myelodysplastic syndrome | 1 (10) | 1 (5) |
| Severe aplastic anemia | 1 (10) | 6 (32) |
| Leukemia stage at transplantation, no. (%) | ||
| First complete remission | 1 (13) | 7 (58) |
| Second complete remission | 5 (62) | 2 (17) |
| First chronic phase | 0 (0) | 3 (25) |
| First acute phase | 2 (25) | 0 (0) |
| Median (range) nucleated cell no. infused (× 108/kg) | 0.29 (0.11-0.70) | 2.93 (0.91-5.74) |
| Median (range) CD34+ cell no. infused (× 105/kg) | 0.14 (0.05-0.38) | 6.08 (2.05-17.86) |
| Conditioning, no. (%) | ||
| Cyclophosphamide based | 8 (80) | 15 (79) |
| Melphalan based | 2 (20) | 4 (21) |
| Total body irradiation | 6 (60) | 6 (32) |
| Antithymocyte globulin | 6 (60) | 5 (26) |
| GVHD prophylaxis, no. (%) | ||
| Cyclosporine | 6 (60) | 0 (0) |
| Cyclosporine + methotrexate | 0 (0) | 19 (100) |
| Cyclosporine + prednisolone | 4 (40) | 0 (0) |
| Posttransplantation G-CSF, no. (%) | 9 (90) | 9 (47) |
G-CSF indicates granulocyte colony-stimulating factor.